Country: EU
Laboratories❯
The site is temporarily down due to maintenance. Sorry for the inconvenience.
The site is temporarily down due to maintenance. Sorry for the inconvenience.
The site is temporarily down due to maintenance. Sorry for the inconvenience.
The site is temporarily down due to maintenance. Sorry for the inconvenience.
Quality & Accuracy
Experience
The latest technologies
Speed &
Credibility
₾160.00
Study material: Venous blood
Response time (working day): 14
The test is done on an empty stomach: no
Home call service: YesHuman Epididymis Protein 4 is a tumor marker used for the diagnostics and monitoring of cervical and ovarian cancer. It is particularly important for the early detection and assessment of progression of epithelial ovarian cancer.
Human epididymal protein 4 (HE4) is synthesized in ovarian epithelial cells. That is why it is a specific marker of ovarian epithelial cell tumors and is used for differential diagnostics and also for monitoring diagnosed epithelial cell tumors. The test determines the concentration of EH4 in the blood serum.
There are several subtypes of epithelial cells: serous, endometrial, mucinous, and clear cell. The most common serous epithelial cell tumors.
The HE4 study may be performed in isolation, or together with CA125, to calculate the ROMA-index.
According to studies, the increase of EH4 is more typical for ovarian serous and endometrial epithelial cell tumors, less for clear cell tumors. And, in the case of mucous tumors, its concentration is almost not increased.
Human epididymal protein 4 (HE4), together with CA-125 carcinoembryonic antigen, is used to monitor ovarian epididymal tumors. The combination of these two studies allows for better monitoring.
The use of HE4 for screening in asymptomatic women is futile because it is a non-specific test. A small amount of HE4 is also synthesized by other cells, so a moderate increase in its concentration is also possible in some non-cancerous diseases.
HE4 and CA125 are part of the ovarian malignancy risk assessment algorithm (ROMA-index), which is a reliable marker for the differential diagnostics of small pelvic bulky processes.
Human epididymal protein: Premenopausal: < 70; Postmenopausal: < 140
Ovarian carcinoma antigenCA125 <35
If before the start of treatment, the concentration of the markers was significantly increased, it is recommended to control the indicators in the dynamics to evaluate the effectiveness of the treatment.
If the indicator was normal before the start of treatment, its monitoring in dynamics is uninformative.
Increased indicators before treatment, decrease in the background of treatment - indicates positive dynamics, i.e. Treatment has results.
If the elevated marker concentration does not change after treatment, this indicates ineffectiveness of the treatment.
After surgical treatment of bulky tumors of the small pelvis, an increase in the ROMA-index probably indicates a malignant process.
In different laboratories, EH4, CA125, ROMA-index studies may be conducted with different methods, therefore, comparing the data of different laboratories in order to observe the dynamics is not recommended. It is always better to compare data from studies conducted in the same laboratory in terms of dynamics.
Study material: Venous blood
The test does not require special preliminary preparation
Response time: 14 working days
Order tests online
Testing process
 |  |
| Purchase a test | Submission of material |
 |  |
| Results Online | Consult a doctor |
